Apnimed to Showcase Oral Therapy AD109 at the World Sleep Congress 2025
Apnimed's Exciting Innovations at the World Sleep Congress 2025
Apnimed, Inc., an innovative pharmaceutical company renowned for developing cutting-edge oral medications targeting the underlying causes of obstructive sleep apnea (OSA), is set to make significant presentations at the upcoming World Sleep Congress in Singapore from September 5 to 10, 2025. The event will serve as a platform to shine a light on AD109, Apnimed's flagship investigational treatment for OSA.
Upcoming Presentations at the World Sleep Congress
During the World Sleep Congress, Apnimed plans to deliver several oral presentations and poster sessions. These will delve into various aspects of OSA and its treatments:
- - Oral Presentation 1:
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.